IV: 3–8 g/m 2 every 1–3 weeks; doses >3 g/ m2 should be given as an infusion Doses up to 1.5 g/m 2 have been given IP Oral: 1 g daily in 4 divided doses for 2–4 weeks or 1.5 g daily in 3 divided doses for 1 week Or according to local protocol
<10           : Use a reduced dose
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                : Unknown dialysability. Dose as in GFR <10 mL/min
HD                     : Dialysed. Dose as in GFR <10 mL/min
HDF/high flux   : Dialysed. Dose as in GFR <10 mL/min
CAV/VVHD      : Unknown dialysability. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
None known
ADMINISTRATION
Reconstition
20 or 100 mL water for injection for 1 g and 5 g vials respectively
Route
Oral, IV, IP
Rate of Administration
3 g/m 2 over 5–10 minutes (8 g/m2 over 30 minutes)
Comments
Powder reconstitutes easier if water heated to 25–30°C
OTHER INFORMATION
Treosulfan is a prodrug of a bifunctional alkylating agent; high and relatively constant bioavailability. Mean urinary excretion of the parent compound is ~15% over 24 hrs Haemorrhagic cystitis has occurred after intravesical or intravenous administration .